Monoclonal gammopathy of undetermined significance (MGUS) is the most prevalent clonal plasma cell proliferative disorder, present in over 3% of the population aged 50 years and older, with a rate of progression to malignancy of 1% per year.
While several genetic variants have been identified for MM, none have been identified that are associated with MGUS. 5 Broderick et al. 6 recently conducted the first genome-wide association study of MM using case-control studies from the United Kingdom and Germany and identified three novel loci at 3p22.1 (rs1052501 in ULK4), 7p15.3 (rs4487645) and 2p23.3 (rs6746082) associated with risk of MM, although the latter did not reach genome-wide significance (Po5 Â 10
). We investigate whether these three loci for MM risk are also associated with risk of MGUS in order to provide evidence that genetic variation influences MM through MGUS. We also attempt to replicate the association of these loci with MM within a case-control study of MM.
The ascertainment of MGUS and MM cases and controls, as well as examination of genetic variation in these populations was approved by the Mayo Clinic Institutional Review Board. MGUS and MM cases were sampled from the Mayo Clinic regional practice. Specifically, all patients from Minnesota, Iowa and Wisconsin who were found to have MGUS on a clinical blood test between 2005 through 2009 were invited to participate. MGUS was diagnosed by serum immunofixation. MGUS cases provided informed consent, blood and questionnaire information. Of 973 eligible MGUS cases, 388 (40%) participated and were used for the current analysis; of these, 318 (81.3%) had a detectable M protein on serum protein electrophoresis. Incident MM cases were sampled from MM cases seen between 1998 and 2007 and within 9 months of their initial diagnosis. Eligible cases had provided prior consent and a blood sample for research studies of MM. A total of 243 MM cases from the seven states, including Minnesota, Iowa, Wisconsin, North Dakota, Michigan, South Dakota and Illinois were used for analyses (Table 1) .
Clinic-based controls (n ¼ 378) who were recruited from the General Internal Medicine clinics between 2002 and 2010 into an ongoing Mayo Clinic case-control study of non-Hodgkin lymphoma 7 were used as the comparison group for both MM and MGUS cases. Controls were at least 20 years old, residents of Minnesota, Iowa or Wisconsin and had no personal history of lymphoma, leukemia or HIV infection, MM or known MGUS ( Table 1) .
Genotyping of the single-nucleotide polymorphisms (SNPs) rs1052501, rs4487645 and rs6746082 was performed using TaqMan SNP Genotyping Assays (Applied Biosystems, Carlsbad, CA, USA). In addition to the 1012 case and control samples, an extra two duplicates and three related controls were genotyped on each plate, with concordance rates 100% for all three SNPs. Sample call rate was 497%. We assessed departures from Hardy-Weinberg equilibrium among controls using an exact test. None of the SNPs showed departure from Hardy-Weinberg equilibrium.
Odds ratios and 95% confidence intervals from logistic regression were used to evaluate the associations between the three SNPs with risk of MGUS and of MM assuming an additive model. Analyses were also performed adjusting for age, and after excluding those who did not have a detectable M protein on serum protein electrophoresis (n ¼ 70).
The SNP at 3p22.1 (rs1052501 in ULK4) was associated with both MGUS and MM (Table 2) . Specifically, the C allele was associated with a 30% increased risk of MGUS (OR ¼ 1.32; 95% CI: 1.02-1.72; P ¼ 0.04) and 40% increased risk of MM (OR ¼ 1.39; 95% CI: 1.04-1.86; P ¼ 0.03), similar to that previously reported. 6 We failed to replicate the associations for rs6746082 and rs4487645 (Table 2) with MM 6 and found no significant association with MGUS. Results (not shown) were virtually unchanged with adjustment for age and when restricted to the 318 MGUS cases who had a detectable M protein on SPEP.
Rs1052501 maps to ULK4, which encodes a kinase with serine/ threonine activity. While recently found to be associated with MM, rs1052501 has also been shown to have associations with essential hypertension in women and Korean populations. 8, 9 Evidence presented here demonstrates that there is a modest association between rs1052501 and MGUS, and suggests that this polymorphism or the causal variant that it represents, may exert its influence on MM through the initiation of the precursor, MGUS. Letters to the editor Whether rs1052501 (or the other two loci) are associated with progression from MGUS to MM needs to be examined. This is the first study to evaluate whether genetic risk factors for MM also influence MGUS. Genetic variants associated with MM may be associated with the initiation of MGUS (the necessary precursor), the progression of MGUS to MM, or both. We were not able to evaluate the association of this SNP with progression. Although there are known biological markers associated with risk of progression from MGUS to MM (including abnormal free light chain ratio and immunoglobulin subtype), it remains difficult to predict which of the 3% of the population with MGUS will progress to malignancy. 1, 10 Genetic variants should be complementary to these predictions.
We did not find an association of either 7p15.3 (rs4487645) or 2p23.3 (rs6746082) with MM or MGUS. Lack of statistical power is certainly a possibility given our sample size; however, our risk estimates for MM were attenuated relative to the studies reported in Broderick et al. who reported risk estimates of 1.38 (95% CI: 1.28-1.50) and 1.29 (95% CI: 1.17-1.42), respectively.
In summary, we have validated the association between 3p22.1 (rs1052501) and MM, and have also shown this polymorphism to be associated with MGUS, the premalignant condition.
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